{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-24-093294","form_type":"8-K","ticker":"GLUE","cik":"0001826457","company_name":"Monte Rosa Therapeutics, Inc.","filed_at":"2024-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.737091+00:00","generated_at":"2026-05-31T11:10:48.171451+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Monte Rosa Q2 net loss $30.3M; cash $267.1M; IND cleared for MRT-6160","bullets":["Net loss $30.3M for Q2 2024 vs $32.0M in Q1; collaboration revenue $4.7M from Roche deal.","Cash, equivalents, securities $267.1M at June 30, 2024; expected to fund operations into H1 2027.","IND accepted by FDA for VAV1-directed MGD MRT-6160; Phase 1 SAD/MAD to start summer with data expected Q1 2025.","MRT-2359 Phase 1/2 dose escalation ongoing at 0.75 mg 21/7 schedule; RP2D determination and updated results expected H2 2024.","Achieved first research milestones and payments from Roche collaboration; $100M public offering completed in May."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-24-093294","json":"https://secwatch.observer/filing/0000950170-24-093294.json","markdown":"https://secwatch.observer/filing/0000950170-24-093294.md","text":"https://secwatch.observer/filing/0000950170-24-093294.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024093294/0000950170-24-093294-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1826457/000095017024093294/glue-20240808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T11:10:48.171451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}